Immuneering Corporation IMRX
Regular-session close
After hours · Nov 20, 7:37 PM ET
- YTD
- -48.63%
- 1 year
- -51.65%
5D -0.23 (-6.25%)
- Market cap
- 218.90M
- EPS (ttm)
- -0.92
- Shares out
- 31.05M
- Forward P/E
- -1.34
- YTD return
- -48.63%
- 1-year return
- -51.65%
- 50-day average
- 2.01
- 200-day average
- 1.84
- Enterprise value
- 2.11M
- Volume
- 1.46M
- Avg volume
- 731.88K
- Open
- 3.38
- Previous close
- 3.45
- Day's range
- 3.29 – 3.54
- 52-week range
- 3.37 – 8.33
- Beta
- -0.40
- Analysts
- Buy
- Price target
- 12.42 (+267.4%)
Key statistics
- Price / book
- 0.71
- Free cash flow
- -31.61M
- Total cash
- 59.73M
- Total debt
- 4.31M
- Return on equity
- -61.81%
- Short % of float
- 9.27%
Fundamental scorecard
5 of 25 checks passed on IMRX’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.54 | -0.49 | +0.05 | +9.26% |
| Aug 6, 2024 | Jun 1, 2024 | -0.51 | -0.47 | +0.04 | +7.84% |
| Aug 6, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.45 | -0.49 | -0.04 | -8.89% |
| May 7, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 1, 2024 | Dec 1, 2023 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | Needham | reit | Buy | Buy |
| Sep 13, 2024 | Needham | reit | Buy | Buy |
| Aug 7, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 7, 2024 | Needham | reit | Buy | Buy |
| May 8, 2024 | Needham | reit | Buy | Buy |
About Immuneering Corporation
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immuneering.com
News
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
Immuneering Presents Additional Data Demonstrating Atebimetinib's Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials Transcript Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer
Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model
Your note
Sign in to keep a note on IMRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERMAN ANN E | Director | Purchase | Mar 17, 2024 | 67,465 |
| BOOKMAN MICHAEL | Officer | Stock Award(Grant) | Mar 14, 2024 | 3,850 |
| BRAKEWOOD HAROLD EUGENE | Officer | Purchase | Mar 21, 2024 | 3,900 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 31, 2024 | 0 |
| FEINBERG PETER | Director | Purchase | Mar 21, 2024 | 1,096,060 |
| HALL BRETT MATTHEW | Officer | Purchase | Mar 19, 2024 | 345,896 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.45% | 1,070,322 | 2.35M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 2.61% | 810,127 | 1.78M | Sep 29, 2024 |
| Morgan Stanley | 1.45% | 449,311 | 988.48K | Sep 29, 2024 |
| Blackrock Inc. | 1.03% | 318,419 | 700.52K | Sep 29, 2024 |
| Millennium Management Llc | 0.79% | 246,270 | 541.79K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 209,641 | 461.21K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 736,188 | 1.62M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.64% | 509,134 | 1.12M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 289,196 | 636.23K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 118,328 | 260.32K | Oct 30, 2024 |
| ETF Series Solutions-Range Cancer Therapeutics ETF | 0.21% | 64,035 | 140.88K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 49,849 | 109.67K | Oct 30, 2024 |
